5'-O-[cyclo-3,5-di(tert-butyl)-6-fluorosaligenyl]-3'-deoxy-3'-fluorothymidine monophosphate | 1150314-72-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5'-O-[cyclo-3,5-di(tert-butyl)-6-fluorosaligenyl]-3'-deoxy-3'-fluorothymidine monophosphate
• 英文别名: 5'-O-[cyclosaligenyl-3,5-di(tert-butyl)-6-fluoro]-3'-deoxy-3'-fluorothymidine
• CAS: 1150314-72-9
• 化学式: C₂₅H₃₃F₂N₂O₇P
• 分子量: 542.517
• InChiKey: HJWOBFOEHNCYBU-FKQDMZCDSA-N

物化性质

• 密度：
  1.34±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.94
• 重原子数：
  37.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  108.85
• 氢给体数：
  1.0
• 氢受体数：
  8.0

反应信息

• 作为产物：
  描述：

  5'-O-[cyclosaligenyl-3,5-di(tert-butyl)-6-fluoro]-3'-deoxy-3'-fluorothymidine 生成 5'-O-[cyclo-3,5-di(tert-butyl)-6-fluorosaligenyl]-3'-deoxy-3'-fluorothymidine monophosphate 、 5'-O-[cyclo-3,5-di(tert-butyl)-6-fluorosaligenyl]-3'-deoxy-3'-fluorothymidine monophosphate
  参考文献：
  名称：

  Radiologic Agents for Monitoring Alzheimer's Disease Progression and Evaluating a Response to Therapy and Processes for the Preparation of Such Agents

  摘要：

  本文披露了包含正电子发射体或伽马辐射放射性卤化物的某些环丝氨基嘧啶核苷酸单磷酸盐，其用于监测阿尔茨海默病的进展并评估对治疗的反应，以及它们的制备过程。

  公开号：

  US20090117041A1

文献信息

• Radiolabeled Cyclosaligenyl Monophosphates of 5-Iodo-2′-deoxyuridine, 5-Iodo-3′-fluoro-2′,3′-dideoxyuridine, and 3′-Fluorothymidine for Molecular Radiotherapy of Cancer: Synthesis and Biological Evaluation
  作者：Zbigniew P. Kortylewicz、Yu Kimura、Kotaro Inoue、Elizabeth Mack、Janina Baranowska-Kortylewicz

  DOI：10.1021/jm201482p

  日期：2012.3.22

  Targeted molecular radiotherapy opens unprecedented opportunities to eradicate cancer cells with minimal irradiation of normal tissues. Described in this study are radioactive cyclosaligenyl monophosphates designed to deliver lethal doses of radiation to cancer cells. These compounds can be radiolabeled with SPECT- and PET-compatible radionuclides as well as radionuclides suitable for Auger electron therapies. This characteristic provides an avenue for the personalized and comprehensive treatment strategy that comprises diagnostic imaging to identify sites of disease, followed by the targeted molecular radiotherapy based on the imaging results. The developed radiosynthetic methods produce no-carrier-added products with high radiochemical yield and purity. The interaction of these compounds with their target, butyrylcholinesterase, depends on the stereochemistry around the P atom. 1050 values are in the nanomolar range. In vitro studies indicate that radiation doses delivered to the cell nucleus are sufficient to kill cells of several difficult to treat malignancies including glioblastoma and ovarian and colorectal cancers.